Stephen T McSorley1, Mark Johnstone2, Colin W Steele2, Campbell S D Roxburgh2, Paul G Horgan2, Donald C McMillan2, David Mansouri2. 1. Academic Unit of Surgery, School of Medicine, University of Glasgow, Level 2, New Lister Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK. s.mcsorley@doctors.org.uk. 2. Academic Unit of Surgery, School of Medicine, University of Glasgow, Level 2, New Lister Building, Glasgow Royal Infirmary, Glasgow, G31 2ER, UK.
Abstract
BACKGROUND: The present study aimed to characterise the prevalence and prognostic impact of normocytic anaemia in patients undergoing curative treatment for colorectal cancer. METHODS: All individuals invited to the first round of bowel cancer screening, diagnosed with colorectal cancer and treated with curative intent from April 2009 to March 2011 in a single health board were included. The modified Glasgow prognostic score (mGPS) was used to quantify preoperative systemic inflammation. Patients were grouped as having microcytic anaemia (Hb < 130 mg/L males, < 120 mg/L females and MCV < 80 fL), normocytic anaemia (Hb < 130 mg/L males, < 120 mg/L females and MCV 80-100 fL), or neither. RESULTS: Of 395,097 patients invited to screening during the study period, 872 were diagnosed with colorectal cancer. Seven hundred seventy-seven patients had FBC measured at diagnosis, of which 78 (10%) had microcytic anaemia, and 180 (23%) normocytic anaemia. On multivariate binary logistic regression, microcytic anaemia was associated with T stage (OR 1.92, 95% CI 1.26-2.91, p = 0.002) and mGPS (OR 1.57, 95% CI 1.10-2.24, p = 0.013), while normocytic anaemia was associated with colonic tumours (OR = 2.51, 95% CI 1.10-4.01, p = 0.025), T stage (OR 1.38, 95% CI 1.05-1.81, p = 0.022), and mGPS (OR 1.52, 95% CI 1.12-2.05, p = 0.007). On univariate Cox regression, there was no significant association between microcytic anaemia and cancer specific survival (CSS) (p = 0.969). Normocytic anaemia was significantly associated with poorer CSS (HR 1.55, 95% CI 1.13-2.12, p = 0.007). CONCLUSIONS: Normocytic anaemia was associated with systemic inflammation and poorer CSS. Inflammation may drive both anaemia and disease recurrence in these patients, and targeting this process may improve both.
BACKGROUND: The present study aimed to characterise the prevalence and prognostic impact of normocytic anaemia in patients undergoing curative treatment for colorectal cancer. METHODS: All individuals invited to the first round of bowel cancer screening, diagnosed with colorectal cancer and treated with curative intent from April 2009 to March 2011 in a single health board were included. The modified Glasgow prognostic score (mGPS) was used to quantify preoperative systemic inflammation. Patients were grouped as having microcytic anaemia (Hb < 130 mg/L males, < 120 mg/L females and MCV < 80 fL), normocytic anaemia (Hb < 130 mg/L males, < 120 mg/L females and MCV 80-100 fL), or neither. RESULTS: Of 395,097 patients invited to screening during the study period, 872 were diagnosed with colorectal cancer. Seven hundred seventy-seven patients had FBC measured at diagnosis, of which 78 (10%) had microcytic anaemia, and 180 (23%) normocytic anaemia. On multivariate binary logistic regression, microcytic anaemia was associated with T stage (OR 1.92, 95% CI 1.26-2.91, p = 0.002) and mGPS (OR 1.57, 95% CI 1.10-2.24, p = 0.013), while normocytic anaemia was associated with colonic tumours (OR = 2.51, 95% CI 1.10-4.01, p = 0.025), T stage (OR 1.38, 95% CI 1.05-1.81, p = 0.022), and mGPS (OR 1.52, 95% CI 1.12-2.05, p = 0.007). On univariate Cox regression, there was no significant association between microcytic anaemia and cancer specific survival (CSS) (p = 0.969). Normocytic anaemia was significantly associated with poorer CSS (HR 1.55, 95% CI 1.13-2.12, p = 0.007). CONCLUSIONS:Normocytic anaemia was associated with systemic inflammation and poorer CSS. Inflammation may drive both anaemia and disease recurrence in these patients, and targeting this process may improve both.
Authors: D Wayne Thomas; Rod F Hinchliffe; Carol Briggs; Iain C Macdougall; Tim Littlewood; Ivor Cavill Journal: Br J Haematol Date: 2013-04-10 Impact factor: 6.998
Authors: Callum G Fraser; Jayne Digby; Paula J McDonald; Judith A Strachan; Francis A Carey; Robert J C Steele Journal: J Med Screen Date: 2011-12-07 Impact factor: 2.136
Authors: Heinz Ludwig; Simon Van Belle; Peter Barrett-Lee; Gunnar Birgegård; Carsten Bokemeyer; Pere Gascón; Paris Kosmidis; Maciej Krzakowski; Johan Nortier; Patrizia Olmi; Maurice Schneider; Dirk Schrijvers Journal: Eur J Cancer Date: 2004-10 Impact factor: 9.162
Authors: Sorina Radulescu; Matthew J Brookes; Pedro Salgueiro; Rachel A Ridgway; Ewan McGhee; Kurt Anderson; Samuel J Ford; Daniel H Stones; Tariq H Iqbal; Chris Tselepis; Owen J Sansom Journal: Cell Rep Date: 2012-08-09 Impact factor: 9.423
Authors: Juha P Väyrynen; Sara A Väyrynen; Päivi Sirniö; Ilkka Minkkinen; Kai Klintrup; Toni Karhu; Jyrki Mäkelä; Karl-Heinz Herzig; Tuomo J Karttunen; Anne Tuomisto; Markus J Mäkinen Journal: J Transl Med Date: 2019-06-13 Impact factor: 5.531
Authors: Mark S Johnstone; Paul Burton; Georgios Kourounis; Jack Winter; Emilia Crighton; David Mansouri; Paul Witherspoon; Karen Smith; Stephen T McSorley Journal: Int J Colorectal Dis Date: 2021-12-21 Impact factor: 2.571
Authors: Anne Tuomisto; Natalja P Nørskov; Päivi Sirniö; Juha P Väyrynen; Shivaprakash J Mutt; Kai Klintrup; Jyrki Mäkelä; Knud Erik Bach Knudsen; Markus J Mäkinen; Karl-Heinz Herzig Journal: Sci Rep Date: 2019-08-01 Impact factor: 4.379
Authors: Stephen T McSorley; John H Anderson; Thomas Whittle; Campbell S Roxburgh; Paul G Horgan; Donald C McMillan; Colin W Steele Journal: Perioper Med (Lond) Date: 2020-06-11
Authors: Rotem Gvirtzman; Dan Meir Livovsky; Esther Tahover; Eran Goldin; Benjamin Koslowsky Journal: World J Surg Oncol Date: 2021-12-08 Impact factor: 2.754